News | NewsLeerink Partners Adds Industry Veteran Andrew Gitkin to Healthcare Investment Banking TeamApril 2024
News | Deal AnnouncementLeerink Partners Serves as Lead-Left Bookrunner for Edgewise Therapeutics’ (Nasdaq: EWTX) $240 Million Follow-On OfferingJanuary 2024
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Immatics’ (Nasdaq: IMTX) $175 Million Follow-On OfferingJanuary 2024
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Viridian Therapeutics’ (Nasdaq: VRDN) $150 Million Follow-On OfferingJanuary 2024
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor to Zentalis Pharmaceuticals (Nasdaq: ZNTL) on its Global Licensing Agreement with Immunome (Nasdaq: IMNM)January 2024
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Keros Therapeutics’ (Nasdaq: KROS) $140 Million Follow-On OfferingJanuary 2024
News | Deal AnnouncementLeerink Partners Serves as Lead Placement Agent for Immunic’s (Nasdaq: IMUX) Up to $240 Million Private PlacementJanuary 2024
News | NewsLeerink Partners Strengthens Healthcare Services and Technology Team with Hire of Philip BoydJanuary 2024
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor for SQZ Biotechnologies’ Asset Sale to STEMCELL TechnologiesDecember 2023
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor for Theseus Pharmaceuticals’ (Nasdaq: THRX) Proposed Acquisition by Concentra Biosciences, LLCDecember 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for AC Immune SA’s (Nasdaq: ACIU) $50 Million Follow-On OfferingDecember 2023